Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer And Cadila Pool Products To Form Equal Stake JV For India Market

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - A deal that has been brewing for nearly two years has finally taken a concrete shape. Germany's Bayer Healthcare and India's Zydus Cadila have agreed to form an equal stake company that will see Bayer move its existing sales and marketing business in India to the new enterprise

You may also be interested in...

Bayer Challenges Nexavar Compulsory License To Natco; Says It Endangers Pharma Research

The German firm says challenges faced by the Indian healthcare system has little or nothing to do with patents

Bayer Expects Big Gains In APAC With Late-stage Pipeline And Zydus Cadila Joint Venture

Bayer expects half of its 43 clinical trials to be ready for the market in the next few years in Southeast Asia.

Bayer Lines Up Investments Worth €1.8 Billion To Expand In Asia

The German conglomerate targets doubling China and India sales by 2015

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts